This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Mezagitamab
- DrugBank Accession Number
- DB16370
- Background
Mezagitamab is under investigation in clinical trial NCT04278924 (Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/chronic Primary Immune Thrombocytopenia).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Anti-Cd38 monoclonal antibody TAK-079
- IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE 1 (2'-PHOSPHO-ADP-RIBOSYL CYCLASE, ANTIGENE CD38))HUMANIZED MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN HUMANIZED(1-453) (HOMO SAPIENS VH (IGHV3-23*01 (89%) (IGHD)-I
- IMMUNOGLOBULIN G1, ANTI-(HUMAN CD38 ANTIGEN) (HUMAN MONOCLONAL AB79 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AB79 .LAMBDA.-CHAIN, DIMER
- Mezagitamab
- External IDs
- TAK 079
- TAK-079
- TAK079
- WHO 11159
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism AADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 inhibitorHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0XMR8L9LOL
- CAS number
- 2227490-52-8
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Active Not Recruiting Treatment Primary Immune Thrombocytopenia (ITP) 1 somestatus stop reason just information to hide 2 Completed Treatment Myasthenia Gravis 1 somestatus stop reason just information to hide 1 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Multiple Myeloma (MM) 1 somestatus stop reason just information to hide 1 Active Not Recruiting Treatment Glomerulonephritis / Kidney Diseases 1 somestatus stop reason just information to hide 1 Completed Other Coronavirus Disease 2019 (COVID‑19) / Systemic Lupus Erythematosus 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion (PubMed:7961800, PubMed:8253715). Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+) (PubMed:16690024). Has cADPR hydrolase activity (PubMed:7961800, PubMed:8253715)
- Specific Function
- Identical protein binding
- Gene Name
- CD38
- Uniprot ID
- P28907
- Uniprot Name
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Molecular Weight
- 34328.145 Da
References
- Fedyk ER, Zhao L, Koch A, Smithson G, Estevam J, Chen G, Lahu G, Roepcke S, Lin J, Mclean L: Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325. doi: 10.1111/bcp.14241. Epub 2020 Feb 22. [Article]
Drug created at December 21, 2020 19:26 / Updated at July 18, 2023 22:58